- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Liminatus Pharma, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 17.03. | Liminatus Pharma Inc.: Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody | 334 | GlobeNewswire (Europe) | CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed... ► Artikel lesen | |
| 04.03. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.02. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.02. | Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering | 3 | GlobeNewswire (USA) | ||
| LIMINATUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 11.02. | Liminatus Pharma, Inc. - S-1, General form for registration of securities | 14 | SEC Filings | ||
| 09.02. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.01. | Liminatus Pharma, Inc. - 8-K, Current Report | 9 | SEC Filings | ||
| 25.11.25 | Liminatus Pharma verstößt gegen NASDAQ-Zulassungsstandards | 11 | Investing.com Deutsch | ||
| 25.11.25 | Liminatus Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | Liminatus Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.10.25 | Liminatus Pharma Inc.: Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation | 7 | GlobeNewswire (USA) | ||
| 25.07.25 | Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies | 417 | GlobeNewswire (Europe) | LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 24.07.25 | Pre-market Movers: Sadot Group, Community Health Systems, Liminatus Pharma, MaxLinear, Incannex Healthcare | 908 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.10 A.M. ET).In the Green Liminatus Pharma, Inc. (LIMN) is up over 25% at... ► Artikel lesen | |
| 22.07.25 | Liminatus Pharma Inc.: Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy | 295 | GlobeNewswire (Europe) | LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 12.06.25 | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | 1.119 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| 05.06.25 | Pre-market Movers: Liminatus Pharma, ZenaTech, CTRL Group Limited, ZJK Industrial, Cibus | 1.513 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Liminatus Pharma, Inc. (LIMN) is up over 83% at $23.29.
ZenaTech... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,000 | -1,71 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 7,180 | +151,93 % | Psyence Biomedical Ltd.: Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| EVOTEC | 5,570 | +0,54 % | Mutares: Exklusiv-Interview - Deutz, Elmos, Evotec, Infineon und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,870 | +13,13 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| BIONTECH | 86,00 | +2,02 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,740 | -0,27 % | Recursion-CEO erläutert KI-Strategie zur Beschleunigung der Medikamentenentwicklung | ||
| GENMAB | 237,90 | -4,23 % | Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,275 | +5,08 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 315,22 | -7,21 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| VALNEVA | 2,601 | -2,00 % | Guggenheim senkt Kursziel für Valneva-Aktie wegen Lyme-Impfstoff auf 11 US-Dollar | ||
| ADMA BIOLOGICS | 10,630 | -0,09 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| BEAM THERAPEUTICS | 30,160 | -1,68 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,970 | -1,42 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat | - Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 6,465 | +10,42 % | Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update | In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was... ► Artikel lesen | |
| CG ONCOLOGY | 65,93 | -2,67 % | CG Oncology, Inc. - 8-K, Current Report |
Das Unternehmen LIMINATUS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,041 (+21,98 %) liegt der Kurs bei 0,227 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIMINATUS PHARMA INC finden Sie auf Wallstreet Online.